Scarica l'app Stockscreener
85.85
5.20%
4.24
Dopo l'orario di chiusura:
82.03
-3.82
-4.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte's 5.2% Surge on $270M Volume Ranks 430th Amid FDA Approval and Strategic Shifts - AInvest
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know - uk.finance.yahoo.com
Incyte stock hits 52-week high at 83.95 USD - Investing.com
The Top 5 Analyst Questions From Incyte’s Q2 Earnings Call - ca.finance.yahoo.com
Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight - Insider Monkey
Semerjian to lead Geron - BioCentury
Incyte EVP Denton sells $45k in shares after option exercise - Investing.com Canada
Incyte EVP Denton sells $45k in shares after option exercise By Investing.com - Investing.com South Africa
Incyte (INCY) Analyst Rating: Wells Fargo Upgrades to Overweight - GuruFocus
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - The Manila Times
Mallinckrodt appoints Incyte’s Christiana Stamoulis as new CFO - Investing.com
Wells Fargo Upgrades Incyte to Overweight From Equalweight, Adjusts Price Target to $89 From $67 - MarketScreener
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis - BioSpace
Incyte CFO Christiana Stamoulis to step down in September - Investing.com
Incyte CFO Christiana Stamoulis to step down in September By Investing.com - Investing.com UK
Argus Research Adjusts Incyte Price Target to $90 From $75 - MarketScreener
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times
Mizuho Securities Adjusts Incyte Price Target to $74 From $70 - MarketScreener
Incyte rises on results beat, lifted Jakafi guidance - MSN
Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat
Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News
What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News
Citigroup Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga
Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com
Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest
Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News
Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - MSN
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Nigeria
Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte: Q2 Earnings Snapshot - Huron Daily Tribune
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize
Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):